Exelixis Inc (EXEL)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 50% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+57% over the past year+6
- 52-week positionPressing 52-week highs+30
- QualityStrong net margin (35%)+7
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst here is analyst activity, with RBC's price-target revisions and valuation commentary around Exelixis's cabozantinib patent window driving the narrative more than any single operational event. Continuation likelihood over the next few weeks appears modest, as mixed target changes and patent-cliff concerns suggest sentiment is more range-bound than directional. Informational only — not financial advice.
- Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and PartneringYahoo · 2026-10-13
- Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on CapitalChartMill · 2026-10-12
- RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $51Benzinga · 2026-10-09
- RBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45Benzinga · 2026-10-08
- Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus?Yahoo · 2026-10-08
Any AI summary is an interpretation of public news, not advice or a price target.